
Lakewood-Amedex Prepares Phase 2a Trial for Nu-3 Diabetic Foot Gel
Sarasota-based Lakewood-Amedex Biotherapeutics has cleared a critical regulatory hurdle, reporting positive preclinical safety data for its Nu-3 gel. The findings confirm that the Bisphosphocin-based treatment is well-tolerated at high doses, setting the stage for imminent Phase 2a clinical trials targeting infected diabetic foot ulcers.



























